CATALOGO DEI PRODOTTI DELLA RICERCA

SENNA, Gianenrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.039
EU - Europa 6.319
AS - Asia 5.189
SA - Sud America 783
Continente sconosciuto - Info sul continente non disponibili 235
AF - Africa 184
OC - Oceania 7
Totale 20.756
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.804
RU - Federazione Russa 2.962
SG - Singapore 2.219
CN - Cina 1.178
IT - Italia 1.097
GB - Regno Unito 630
BR - Brasile 587
VN - Vietnam 511
HK - Hong Kong 481
FR - Francia 339
DE - Germania 326
SE - Svezia 270
IE - Irlanda 263
BD - Bangladesh 197
KR - Corea 155
FI - Finlandia 142
CA - Canada 132
IN - India 109
JP - Giappone 70
AR - Argentina 65
MX - Messico 59
NL - Olanda 52
ZA - Sudafrica 43
ES - Italia 42
ID - Indonesia 42
TR - Turchia 42
UA - Ucraina 40
PL - Polonia 35
IQ - Iraq 32
NG - Nigeria 30
CO - Colombia 29
VE - Venezuela 28
TG - Togo 26
BJ - Benin 25
AT - Austria 23
EC - Ecuador 23
SA - Arabia Saudita 22
BE - Belgio 20
CL - Cile 20
PK - Pakistan 17
MA - Marocco 15
UZ - Uzbekistan 13
PH - Filippine 12
CR - Costa Rica 11
JO - Giordania 11
PY - Paraguay 11
JM - Giamaica 10
LT - Lituania 10
AZ - Azerbaigian 9
KE - Kenya 9
MY - Malesia 9
NP - Nepal 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
HN - Honduras 7
IL - Israele 7
NO - Norvegia 7
PE - Perù 7
PT - Portogallo 7
AU - Australia 6
CZ - Repubblica Ceca 5
DZ - Algeria 5
EE - Estonia 5
EG - Egitto 5
KZ - Kazakistan 5
LB - Libano 5
SN - Senegal 5
AL - Albania 4
BG - Bulgaria 4
DK - Danimarca 4
RO - Romania 4
SC - Seychelles 4
TH - Thailandia 4
TN - Tunisia 4
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
BZ - Belize 2
DM - Dominica 2
ET - Etiopia 2
EU - Europa 2
GP - Guadalupe 2
GY - Guiana 2
HR - Croazia 2
LK - Sri Lanka 2
MD - Moldavia 2
MG - Madagascar 2
ML - Mali 2
PA - Panama 2
RS - Serbia 2
TT - Trinidad e Tobago 2
Totale 20.498
Salva come PNG Salva come JPEG
Città #
Singapore 1.151
Ashburn 1.120
San Jose 999
Moscow 996
Dallas 772
Chandler 627
Hong Kong 472
Southend 422
Council Bluffs 360
New York 335
Verona 318
Beijing 267
Dublin 258
The Dalles 248
Jacksonville 161
Los Angeles 155
Ho Chi Minh City 151
Woodbridge 145
Hanoi 113
Princeton 110
Lawrence 109
Houston 99
Wilmington 91
Munich 89
Buffalo 87
Santa Clara 80
Milan 79
Ann Arbor 75
Sindelfingen 74
São Paulo 62
Tokyo 62
Helsinki 60
Jinan 60
London 57
Rome 54
Shenyang 53
Redondo Beach 52
Columbus 49
Denver 43
Boardman 39
Bologna 39
Nanjing 39
Montreal 38
Redmond 37
Chennai 36
Hebei 36
Brooklyn 35
Guangzhou 35
Orem 34
Seattle 34
Johannesburg 32
Warsaw 30
Abuja 29
Haiphong 29
Turku 29
Amsterdam 28
Toronto 28
Chicago 27
Redwood City 27
Changsha 26
Ningbo 26
Poplar 26
Atlanta 25
Cotonou 25
Da Nang 25
Lomé 25
Tianjin 25
Naples 24
Phoenix 24
Rio de Janeiro 24
Kent 23
San Francisco 23
Stockholm 23
Haikou 22
Nanchang 21
Norwalk 21
Cleveland 20
Dong Ket 20
Frankfurt am Main 20
Nuremberg 20
Mumbai 19
Taizhou 19
Mexico City 18
Taiyuan 18
Boston 17
Brussels 17
Hangzhou 17
Zhengzhou 17
Falkenstein 15
Jakarta 15
Manchester 15
McKinney 15
Turin 15
Bari 14
Padova 14
Ankara 13
Baghdad 13
Tashkent 13
Florence 12
Las Vegas 12
Totale 11.972
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 472
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 237
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels 222
Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenopteria allergy 219
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management 218
Fatal asthma; is it still an epidemic? 216
La salute del respiro: epidemiologia, costi sanitari ed implicazioni sociali delle malattie respiratorie croniche in Europa e in Italia 214
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 202
Study on the Immunoreactivity of Triticum monococcum (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods 201
Allergic rhinitis: pharmacotherapy in pregnancy and old age 193
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 190
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 187
Allergy and the bone: unexpected relationships 186
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 185
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 184
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 180
Adverse reaction to local anaesthetics: Is it always allergy? 180
Analysis of the positivity rate in IgE positive patients to inhalant allergens in Verona Hospital Laboratory during 2002-2003 171
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 170
A double-blind placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 169
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 167
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 167
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 163
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 163
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 162
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 162
Periostin: The bone and beyond 161
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 161
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 160
Allergen-specific immunotherapy and COVID-19: What happened? 158
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 157
Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study 156
Biologics and global burden of asthma: A worldwide portrait and a call for action 155
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 155
Impatto socio-sanitario e livello del controllo delle patologie respiratorie croniche ostruttive e della rinite in Italia 154
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 154
Anaphylaxis and intimate behaviour 154
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 153
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 153
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 152
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 150
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 149
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 147
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 145
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 145
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 143
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 143
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 143
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 142
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 142
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 142
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 140
COPD prevalence in a north-eastern Italian general population 140
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 139
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies 139
Multidisciplinary management in type 2 inflammatory disease 139
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 135
Systemic Reactions After Hymenoptera Sting And Raised Serum Tryptase Strongly Suggest Clonal Mast Cells Disorders 132
Uncontrolled Asthma: Unmet Needs in the Management of Patients 131
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 130
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 130
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 128
Diagnosis, management and therapeutic options for eosinophilic esophagitis 128
What lies beyond Asthma Control Test: Suggestions for clinical practice 128
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 128
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 127
Omalizumab management beyond clinical trials: the added value of a network model 127
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 127
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 127
Anaphylaxis due to antiallergic and antiasthmatic biologics 126
Scombroid syndrome: it seems to be fish allergy but... it isn't 125
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 124
Is hymenoptera venom allergy an occupational disease? 124
Potential benefit of omalizumab in respiratory diseases 124
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 124
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 122
How much specific is the association between hymenoptera venom allergy and mastocytosis? 122
Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies 121
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 121
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 121
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 121
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 120
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 120
One year of mepolizumab. Efficacy and safety in real-life in Italy 120
Asthma management among different specialists: results from a national Italian survey 120
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 120
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address 119
Asthma severity: the patient’s point of view 118
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 118
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 118
IgE to staphylococcal enterotoxins are undetectable in sera from patients with nasal polyposis 117
Targeting eosinophils: severe asthma and beyond 117
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 117
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 115
Sex in Respiratory and Skin Allergies 114
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 114
The degree of serological sensitization to cat allergen in patients with or without cat at home 113
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 113
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI 113
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 113
Totale 15.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.102
article - articoli 77.742
book - libri 583
conference - conferenze 313
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 464
Totale 158.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022436 0 0 0 45 16 14 15 48 50 13 51 184
2022/20231.854 139 158 190 266 179 421 30 108 222 15 86 40
2023/20241.341 52 95 119 168 113 283 89 63 20 59 191 89
2024/20253.192 159 181 151 445 122 99 119 255 496 234 263 668
2025/202610.501 685 642 723 1.739 2.649 664 874 577 774 517 283 374
2026/20271.398 121 305 330 642 0 0 0 0 0 0 0 0
Totale 20.756